Cellect Biotechnology, a developer of stem cells isolation technology, said Monday that it has received a formal notice of allowance for a patent covering a key composition of matter and method of use. The company said that this new patent significantly enhances the protection of its core technology and its commercial applications by covering the various devices using the ApoGraft for selection of stem cells. Specifically, the patent is expected to give the company full protection against any devices that make use of apoptosis for cell selection and is also expect to protect the method for using the device.
Devices using the ApoGraft are designed to enable single step cell selection in a simplified setting by an off-the-shelf product – a solution that currently does not exist and covering a wide range of unmet medical needs. These devices are essentially containers (a bag, column, tube, bottle, vial, flask or bioreactor) comprised of a biocompatible material and a biologically active apoptosis-inducing ligand immobilized to a surface in the inner side of the container. The device is adapted to cell selection of apoptosis-sensitive cells.